Medtronic's Altaviva wins FDA approval as a minimally invasive implant for urge urinary incontinence, offering long-lasting and low-maintenance therapy.

Bladder cancer patients who have an early but aggressive form of the disease that’s unresponsive to the standard of care now have a new treatment option, an implanted Johnson & Johnson drug/device ...

Implantation of the device is minimally invasive, requiring no sedation or imaging, and is conducted near the ankle.

To make life easier for people with a common bladder condition, Medtronic is digging in far away from urinary tract.

The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...

(Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug ...

The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland, Sept. 19, 2025 /PRNewswire ...

Radiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, ...

Sept 10 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's (JNJ.N), opens new tab drug delivery system for a type of bladder cancer, offering a potential surgery-free ...

GALWAY, Ireland - Medtronic plc (NYSE:MDT), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $122.6 billion, announced today it has received U.S. Food ...

NEW YORK CITY — The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a ...